Showing results (891-900 of 3,354) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|February 14, 2012
Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational studyFrédéric Amant, Kristel Van Calsteren, Michael J Halaska, et al.
The Lancet. Oncology|October 1, 2011
Delivering affordable cancer care in high-income countriesRichard Sullivan, Jeffrey Peppercorn, Karol Sikora, et al.
The Lancet. Oncology|October 29, 2011
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trialAnas Younes, Yasuhiro Oki, R Gregory Bociek, et al.
The Lancet. Oncology|April 20, 2012
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trialLi Zhang, Shenglin Ma, Xiangqun Song, et al.
The Lancet. Oncology|March 24, 2012
Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trialsAnnemijn M Algra, Peter M Rothwell
The Lancet. Oncology|January 31, 2012
Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trialXin Shelley Wang, Laurence D Rhines, Almon S Shiu, et al.
The Lancet. Oncology|April 4, 2012
Evaluation of novel radiotherapy technologies: what evidence is needed to assess their clinical and cost effectiveness, and how should we get it?Judith van Loon, Janneke Grutters, Fergus Macbeth
The Lancet. Oncology|April 2, 2011
Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registriesAmy Berrington de Gonzalez, Rochelle E Curtis, Stephen F Kry, et al.
The Lancet. Oncology|July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialGareth J Morgan, J Anthony Child, Walter M Gregory, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Pageof 336